Duavee is owned by Wyeth Pharms.
Duavee contains Bazedoxifene Acetate; Estrogens, Conjugated.
Duavee has a total of 2 drug patents out of which 0 drug patents have expired.
Duavee was authorised for market use on 03 October, 2013.
Duavee is available in tablet;oral dosage forms.
Duavee can be used as prevention of postmenopausal osteoporosis; treatment of moderate to severe vasomotor symptoms associated with menopause.
The generics of Duavee are possible to be released after 10 March, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7683051||WYETH PHARMS||Crystalline polymorph of bazedoxifene acetate|| |
(3 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6479535||WYETH PHARMS||2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations|| |
(1 year, 1 month from now)
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
Market Authorisation Date: 03 October, 2013
Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic